ENTRY       D03218                      Drug
NAME        Axitinib (JAN/USAN);
            Inlyta (TN)
PRODUCT     INLYTA (Pfizer Laboratories Div Pfizer)
            INLYTA (U.S. Pharmaceuticals)
FORMULA     C22H18N4OS
EXACT_MASS  386.1201
MOL_WEIGHT  386.4695
CLASS       Antineoplastic
             DG01918  Tyrosine kinase inhibitor
              DG01917  Receptor tyrosine kinase inhibitor
               DG03203  VEGFR inhibitor
            Metabolizing enzyme substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
             DG02925  CYP3A5 substrate
REMARK      Therapeutic category: 4291
            ATC code: L01EK01
            Product: D03218<JP/US>
EFFICACY    Antineoplastic, Receptor tyrosine kinase inhibitor
  DISEASE   Renal cell carcinoma [DS:H00021]
TARGET      VEGFR1 (FLT1) [HSA:2321] [KO:K05096]
            VEGFR2 (KDR) [HSA:3791] [KO:K05098]
            VEGFR3 (FLT4) [HSA:2324] [KO:K05097]
  PATHWAY   hsa04010(2321+2324+3791)  MAPK signaling pathway
            hsa04370(3791)  VEGF signaling pathway
            hsa05200(2324)  Pathways in cancer
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP3A5 [HSA:1577]
INTERACTION  
STR_MAP     map07045  Antineoplastics - protein kinase inhibitors
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L01 ANTINEOPLASTIC AGENTS
               L01E PROTEIN KINASE INHIBITORS
                L01EK Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
                 L01EK01 Axitinib
                  D03218  Axitinib (JAN/USAN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antineoplastics
              Molecular Target Inhibitors
               Axitinib
                D03218  Axitinib (JAN/USAN)
            Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              42  Antineoplastics
               429  Miscellaneous
                4291  Other Antitumors
                 D03218  Axitinib (JAN/USAN)
            Drug groups [BR:br08330]
             Antineoplastic
              DG01918  Tyrosine kinase inhibitor
               DG01917  Receptor tyrosine kinase inhibitor
                DG03203  VEGFR inhibitor
                 D03218  Axitinib
             Metabolizing enzyme substrate
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D03218  Axitinib
              DG02925  CYP3A5 substrate
               D03218  Axitinib
            Target-based classification of drugs [BR:br08310]
             Protein kinases
              Receptor tyrosine kinases (RTK)
               VEGFR family
                VEGFR1 (FLT1)
                 D03218  Axitinib (JAN/USAN) &lt;JP/US&gt;
                VEGFR2 (KDR)
                 D03218  Axitinib (JAN/USAN) &lt;JP/US&gt;
                VEGFR3 (FLT4)
                 D03218  Axitinib (JAN/USAN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D03218
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D03218
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D03218
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D03218
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D03218
DBLINKS     CAS: 319460-85-0
            PubChem: 17397371
            ChEBI: 66910
            PDB-CCD: AXI
            LigandBox: D03218
            NIKKAJI: J2.302.956A
ATOM        28
            1   C8y C    13.1600  -21.9100
            2   C8x C    13.1600  -23.3100
            3   C8x C    14.4200  -24.0100
            4   C8y C    15.6100  -23.3100
            5   C8y C    15.6100  -21.9100
            6   C8x C    14.4200  -21.2100
            7   C8y C    16.9400  -23.7300
            8   N5x N    17.7800  -22.6100
            9   N4x N    16.9400  -21.4900
            10  S2a S    11.9700  -21.2100
            11  C8y C    10.7800  -21.9100
            12  C8y C     9.5900  -21.2100
            13  C8x C     8.3300  -21.9100
            14  C8x C     8.3300  -23.3100
            15  C8x C     9.5200  -24.0100
            16  C8x C    10.7800  -23.3100
            17  C5a C     9.5900  -19.8100
            18  N1b N     8.3300  -19.1100
            19  O5a O    10.7800  -19.1100
            20  C1a C     7.1400  -19.8100
            21  C2b C    16.9400  -25.2000
            22  C2b C    18.2000  -25.9000
            23  C8y C    18.2172  -27.2999
            24  N5x N    17.0008  -28.0224
            25  C8x C    17.0181  -29.4223
            26  C8x C    18.2391  -30.1073
            27  C8x C    19.4556  -29.3847
            28  C8x C    19.4382  -27.9848
BOND        31
            1     1   2 2
            2     2   3 1
            3     3   4 2
            4     4   5 1
            5     5   6 2
            6     1   6 1
            7     4   7 1
            8     7   8 2
            9     8   9 1
            10    5   9 1
            11    1  10 1
            12   10  11 1
            13   11  12 2
            14   12  13 1
            15   13  14 2
            16   14  15 1
            17   15  16 2
            18   11  16 1
            19   12  17 1
            20   17  18 1
            21   17  19 2
            22   18  20 1
            23    7  21 1
            24   21  22 2
            25   22  23 1
            26   23  24 2
            27   24  25 1
            28   25  26 2
            29   26  27 1
            30   27  28 2
            31   23  28 1
///
